“…482,483 In contrast, the significance of estrogen signaling within the ovary is not well understood due to the inherent difficulties associated with the study of a particular hormone's action within the very tissue from which it is synthesized and secreted. Past in vivo investigations employing ER antagonists [217][218][219]484 or aromatase inhibitors [484][485][486] to inhibit hormone receptor actions within the ovary have provided informative but often equivocal findings 217-219 due to the following limitations: (1) the enormous levels of endogenous E2 in the ovary are difficult to overcome by pharmacological administration of a receptor antagonist, (2) the enormous levels of aromatase activity in the ovary are difficult to overcome by pharmacological administration of an enzyme inhibitor, (3) the effects of a pharmacological ER antagonist due to actions directly in the ovary versus actions in the hypothalamus or pituitary are difficult to discern, (4) the well-characterized agonists (e.g., E2 and DES) comparably activate both ERα and ERβ, (5) early antagonists were not selective for the two known ERs, and (6) the two ERs may respond differently to agonist or antagonist ligands.…”